Salvage treatment with upfront melphalan 100 mg/m2 and consolidation with novel drugs for fulminant progression of multiple myeloma

Annals of Hematology

Volumn 89, Issue 5, 2010, Pages 483-487

  Krejci, Marta ^a   Adam, Zdenek ^a   Buchler, Tomas ^b   Krivanova, Andrea ^a   Pour, Ludek ^a   Zahradova, Lenka ^a   Holanek, Michal ^a   Sandecka, Viera ^a   Mayer, Jiri ^a   Vorlicek, Jiri ^a   Hajek, Roman ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^b CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Fulminant progression; Melphalan; Multiple myeloma; Novel drugs

Indexed keywords

ANTIBIOTIC AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BACTERIAL PNEUMONIA; BONE MARROW; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CELL INFILTRATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; HUMAN; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEUROTOXICITY; NEUTROPHIL COUNT; OVERALL SURVIVAL; PANCYTOPENIA; PARESTHESIA; PNEUMONIA; PRIORITY JOURNAL; SEDATION; SIDE EFFECT; SINUSITIS; SKIN TINGLING; THROMBOCYTE COUNT; COMPARATIVE STUDY; DISEASE COURSE; DRUG ADMINISTRATION; FOLLOW UP; METHODOLOGY; MIDDLE AGED; PATHOLOGY; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FOLLOW-UP STUDIES; HUMANS; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; RETROSPECTIVE STUDIES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 77950578084     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00277-009-0862-z     Document Type: Article

References (20)

1. B Bruno M Rotta L Giaccone, et al. 2004 New drugs for treatment of multiple myeloma Lancet Oncol 5 430 432 10.1016/S1470-2045(04)01511-6 1:CAS:528:DC%2BD2cXlsVSit74%3D 15231250 (Pubitemid 38878047)
2. A Palumbo I Avonto B Bruno, et al. 2006 Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma Eur J Haematol 76 273 277 10.1111/j.1600-0609.2005.00610.x 1:CAS:528: DC%2BD28XkvVOkurw%3D 16519697 (Pubitemid 43362934)
3. A Palumbo MT Ambrosini G Benevolo, et al. 2007 Bortezomib, melphalan, prednisone and thalidomide for relapsed multiple myeloma Blood 109 2767 2672 1:CAS:528:DC%2BD2sXjvVynsrg%3D 17148584
4. M Zemanova V Scudla Z Adam, et al. 2008 Low-dose thalidomide regimens in therapy of relapsed or refractory multiple myeloma Neoplasma 55 345 349 1:CAS:528:DC%2BD1cXovFOjtb0%3D 18505347
5. 2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma Clin Lymphoma Myeloma 6 475 477 10.3816/CLM.2006.n.028 1:CAS:528:DC%2BD28XntVeksb0%3D 16796778
6. 2 in fulminant progression of multiple myeloma Haematologica 92 suppl 1 abstract 262
7. B Durie S Salmon 1975 A clinical staging system for multiple myeloma Cancer 36 842 854 10.1002/1097-0142(197509)36:3<842::AID-CNCR2820360303>3. 0.CO;2-U 1:STN:280:DyaE28%2FktFCqtA%3D%3D 1182674
8. PR Greipp J San Miguel BG Durie, et al. 2005 International staging system for multiple myeloma J Clin Oncol 23 3412 3420 10.1200/JCO.2005.04.242 15809451
9. J Blade D Samson D Reece, et al. 1998 Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT Br J Haematol 102 1115 1123 10.1046/j.1365-2141.1998.00930.x 1:STN:280:DyaK1cvitl2mtw%3D%3D 9753033 (Pubitemid 28435189)
10. BG Durie JL Harousseau JS Miguel, et al. 2006 International uniform response criteria for multiple myeloma Leukemia 20 1467 1473 10.1038/sj.leu.2404284 1:STN:280:DC%2BD28rgt1aqtA%3D%3D 16855634 (Pubitemid 44264086)
11. AK Stewart PL Bergsagel PR Greipp, et al. 2007 A practical guide to defining high-risk myeloma for clinical trials, patients counseling and choice of therapy Leukemia 21 529 534 10.1038/sj.leu.2404516 1:STN:280: DC%2BD2s7htFWhuw%3D%3D 17230230
12. Cancer Therapy Evaluation Program. Common terminology criteria for adverse event v 3.0 DCTD, NCI, NIH, DHHD, 2003. URL http://ctep.cancer.gov.
13. S Lenhoff M Hjorth I Turesson, et al. 2006 Intensive therapy for multiple myeloma in patients younger than 60 years. Long-term results focusing on the effect of the degree of response on survival and relapse pattern after transplantation Haematologica 91 1228 1233 1:CAS:528:DC%2BD28XhtVOhtL%2FE 16956822
14. A Palumbo T Facon P Sonneveld, et al. 2008 Thalidomide for treatment of multiple myeloma: 10 years later Blood 111 3968 3977 10.1182/blood-2007-10- 117457 1:CAS:528:DC%2BD1cXkvFeju7c%3D 18245666
15. FE Davies P Wu M Jenner, et al. 2007 The combination of cyclophospshamide, velcade and dexamethasone induces high response rates with comparable toxicity to velcade alone and velcade plus dexamethasone Haematologica 92 1149 1150 10.3324/haematol.11228 1:CAS:528:DC%2BD2sXhtFKrs77J 17650451 (Pubitemid 350144228)
16. R Garzia-Sanz JR Gonzalez-Porras JM Hemandes, et al. 2004 The oral combination of thalidomide, cyclophosphamide and dexamethasone is effective in relapsed/refractory multiple myeloma Leukemia 18 856 863 10.1038/sj.leu.2403322 (Pubitemid 38500205)
17. C Kyriakou K Thomson S D́Sa, et al. 2005 Low dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma Br J Hematol 129 763 770 10.1111/j.1365-2141.2005.05521.x 1:CAS:528:DC%2BD2MXms1ehsL4%3D (Pubitemid 40904526)
18. M Roussou A Anagnostopoulos E Kastritis, et al. 2007 Pulsed cyclophosphamide, thalidomide and dexamethasone regimen for previously treated patients with multiple myeloma: long term follow up and disease control after subsequent treatments Leuk Lymphoma 48 754 758 10.1080/10428190601186168 1:CAS:528:DC%2BD2sXnsVSjurY%3D 17454634 (Pubitemid 46605548)
19. JF San-Miguel PG Richardson P Sonneveld, et al. 2008 Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study Leukemia 22 842 849 10.1038/sj.leu.2405087 1:CAS:528:DC%2BD1cXks12rtLw%3D 18200040 (Pubitemid 351552634)
20. P Tosi E Zamagni C Cellini, et al. 2004 Thalidomide alone or in combination with dexamethasone in patients with advanced, relapsed or refractory multiple myeloma and renal failure Eur J Haematol 73 98 103 10.1111/j.1600-0609.2004.00272.x 1:CAS:528:DC%2BD2cXmvVaisr4%3D 15245508 (Pubitemid 38980109)